Abstract: The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-borne encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds.

Abstract: Methods of using small molecule inhibitors of fatty acid oxidation (FAO) as antimicrobials against intracellular Mycobacteria are disclosed. FAO inhibitors including etomoxir, trimetazidine, oxfenicine perhexeline and/or can be used alone, or in combination with known as antimycobacterial agents against intracellular Mycobacteria.

Abstract: The present invention is related to a dual promoter lentiviral vector and methods of use for the treatment of diseases and disorders, specifically lysosomal storage disorders.

Abstract: Provided are implantable biomedical devices and related methods for interfacing with a target tissue. The devices comprise a substrate, an electronic device supported by the substrate and a freely positionable injectable needle electronically connected to the electronic device by a deformable interconnect, where the injectable needle has one or more optical sources provided on a distal tip end. The injectable needle may further comprise a photodetector.

Abstract: Described is a composition that includes: (i) a drug against tuberculosis inhibiting the cytochrome b subunit of the bc1 complex, said cytochrome b subunit being encoded by the gene qcrB, in Mycobacterium tuberculosis, or a pharmaceutically acceptable salt thereof, and (ii) a compound of Formula II, or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure is generally related to neurofibromatosis type 1. More particularly, disclosed herein are methods for detecting behavioral disorders, methods for detecting cognitive impairment, and methods for detecting brain neurofibromin-dependent dopaminergic signaling associated with neurofibromatosis type 1.

Abstract: An arteriovenous graft and methods of reducing the risk of graft thrombosis and extending patency of the arteriovenous graft are provided herein. The arteriovenous graft is operable for attaching to a vein at a venous anastomosis. In some aspects, the arteriovenous graft includes a plurality of grooves at a venous anastomosis end of the arteriovenous graft and the venous anastomoses may be arranged such that the arteriovenous graft and the vein meet at an angle of 30° or less.

Abstract: A pharmaceutical composition includes a small molecule and a pharmaceutically acceptable excipient. The small molecule interacts with a deoxyxylulose phosphate reductoisomerase (Dxr). A method for treating or preventing a microbial infection in a subject in need thereof includes administering the pharmaceutical composition. A method for inhibiting the growth of a eukaryotic pathogen includes contacting the eukaryotic pathogen with an effective amount of the pharmaceutical composition.

Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions, and methods for treating or preventing microbial infection caused by parasites or bacteria, such as Plasmodium falciparum or related Plasmodium parasite species and Mycobacterium tuberculosis or related Mycobacterium bacteria species. The compounds are ?,?-unsaturated analogs of fosmidomycin and can inhibit deoxyxylulose phosphate reductoisomerase (Dxr) in many microbes, such as P. falciparum.

Abstract: Provided are implantable, injectable and/or surface mounted biomedical devices and related methods for interfacing with a target tissue. The devices have a substrate, one or more microfluidic channels embedded in or supported by the substrate and a fluid actuator in operational communication with one or more reservoirs and responsive to a wireless control signal. The components of the device are specially configured and packaged to be ultra-thin and mechanically compliant. In some embodiments, the devices are self-powered and fully implantable. The devices can be shaped to provide injection in a minimally invasive manner, thereby avoiding unnecessary tissue damage and providing a platform for long-term implantation for interfacing with biological tissue.

Abstract: Plasmonic nanotransducers, methods of preparing plasmonic nanotransducers, and methods for label-free detection of target molecules are disclosed. The plasmonic nanotransducers include hollow nanostructure cores and artificial antibodies. The plasmonic nanotransducers are exposed to a biological sample that can contain the specific target molecules. The plasmonic nanotransducers can be analyzed with surface enhanced Raman scattering techniques and/or localized surface plasmon resonance techniques to quantify the amount of the target molecule in the sample.

Abstract: A pharmaceutical composition includes a small molecule and a pharmaceutically acceptable excipient. The small molecule interacts with a deoxyxylulose phosphate reductoisomerase (Dxr). A method for treating or preventing a microbial infection in a subject in need thereof includes administering the pharmaceutical composition. A method for inhibiting the growth of a eukaryotic pathogen includes contacting the eukaryotic pathogen with an effective amount of the pharmaceutical composition.

Abstract: A non-transitory computer readable medium stores instructions that, when executed by at least one processor, cause the at least one processor to perform a method that includes computing a transfer matrix representing a relative influence that each respective electrode location for measuring electrical potentials on a patient's body has on an estimation of electrical potentials for locations on a surface of interest prior to the measuring of electrical potentials at the respective electrode locations and receiving electrical potential measurements measured via a plurality of electrodes at respective electrode locations on the patient's body. The method also includes computing the estimation of electrical potentials for the locations on the surface of interest based at least in part on the received electrical potential measurements and the computed transfer matrix and generating image data representing the estimation of electrical potentials.

Abstract: Natural and/or synthetic antibodies for specific proteins are adhered to nanoparticles. The nanoparticles are adhered to a substrate and the substrate is exposed to a sample that may contain the specific proteins. The substrates are then tested with surface enhanced Raman scattering techniques and/or localized surface plasmon resonance techniques to quantify the amount of the specific protein in the sample.

Abstract: A computer-implemented method for electrocardiographic imaging (ECGI) is provided. The method includes computing a transfer matrix, measuring a plurality of electrical potentials, and computing an estimation of electrical potentials on a surface of interest based at least in part on the measured potentials and the computed transfer matrix. The transfer matrix computing step is performed prior to the measuring step.

Abstract: A functional biologically active particle conjugate useful for diagnosis and treating cancer as a bioportal comprises a nanoscale particle having associated therewith an intracellular targeting ligand comprising a PNA, or another nuclease resistant oligonucleotide analog such as MOE-mRNA (2?-methoxyethyl mRNA) or LNA (locked nucleic acid), having a sequence that binds selectively to an uniquely expressed or overexpressed mRNA specific to the cancer or disease state in a living mammal. In one aspect the uniquely overexpressed target specific to the cancer or disease state is the unr mRNA which can be targeted by the antisense sequence PNA50.

Abstract: A probe for use with an imaging system, including a scanning device configured to receive a first light beam from a light source, a beam-divider configured to split the first light beam into a plurality of second light beams, and a focusing device configured to focus each of the second light beams on respective locations in an object of interest is disclosed.

Abstract: Provided are devices and methods capable of interfacing with biological tissues, such as organs like the heart, in real-time and using techniques which provide the ability to monitor and control complex physical, chemical, biochemical and thermal properties of the tissues as a function of time. The described devices and methods utilize micro scale sensors and actuators to spatially monitor and control a variety of physical, chemical and biological tissue parameters, such as temperature, pH, spatial position, force, pressure, electrophysiology and to spatially provide a variety of stimuli, such as heat, light, voltage and current.

Abstract: The invention provides methods for identifying a compound that inhibits cytochrome c synthesis. This invention further provides a method for the high throughput screening of compounds that inhibit cytochrome c synthesis.

Abstract: In one aspect, the disclosure provides isolated nucleic acids, polypeptides, primers, and probes for the detection of mutations in a nucleic acid sequence for a DICER1 polypeptide.